| Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma. | |
| | |
MedLine Citation:
|
PMID: 20401967 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The inhibitors of the mammalian target of rapamycin (mTOR) improve outcomes in patients with advanced renal cell carcinoma. These agents are associated with unusual class-adverse events that represent a challenge to the clinician, making it critical to recognize and treat them appropriately. This study aims to highlight the clinical management of these toxicities by presenting evidence from the literature and suggesting treatment recommendations. A critical review of the literature is performed and a summary of the most relevant emergent toxicities and their management is presented. Treatment recommendations of metabolic disturbances induced by mTOR inhibitors, such as hypophosphatemia, hyperglycemia, and hyperlipidemia along with the management of drug-induced pneumonitis and possible pharmacological interactions are presented. Most of these toxicities, if recognized and treated accordingly, should resolve with minimal impact on patients' quality of life and in the efficacy of this anticancer therapy. Oncologists should be familiar with the recognition and appropriate medical management of these clinical scenarios. |
| | |
Authors:
|
Jesus Rodriguez-Pascual; Elaine Cheng; Pablo Maroto; Ignacio Duran |
Related Documents
:
|
20014417 - Bloodless surgery in gynecologic oncology. 1790457 - The idealisation of therapy: fantasy versus reality in clinical practice. 19941227 - The role of collaborative self-management in pulmonary rehabilitation. 1568147 - Perioperative fluid management. 18084107 - Biotypology, endocrinology, and sterilization: the practice of eugenics in the treatmen... 19185197 - Emergency management during disasters for small animal practitioners. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Anti-cancer drugs Volume: 21 ISSN: 1473-5741 ISO Abbreviation: Anticancer Drugs Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-04-16 Completed Date: 2010-05-13 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9100823 Medline TA: Anticancer Drugs Country: England |
Other Details:
|
Languages: eng Pagination: 478-86 Citation Subset: IM |
Affiliation:
|
Centro Integral Oncologico Clara Campal, Madrid, Spain. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibiotics, Antineoplastic
/
adverse effects*,
pharmacology,
therapeutic use Carcinoma, Renal Cell / drug therapy* Humans Intracellular Signaling Peptides and Proteins / antagonists & inhibitors* Kidney Neoplasms / drug therapy* Protein-Serine-Threonine Kinases / antagonists & inhibitors* Sirolimus / adverse effects*, analogs & derivatives, pharmacology, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antibiotics, Antineoplastic; 0/Intracellular Signaling Peptides and Proteins; 0/ridaforolimus; 0/temsirolimus; 159351-69-6/everolimus; 53123-88-9/Sirolimus; EC 2.7.1.-/mTOR protein; EC 2.7.11.1/Protein-Serine-Threonine Kinases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Characterization of poly(ethylene glycol) gels with added collagen for neural tissue engineering.
Next Document: Compliance of child care centers in Pennsylvania with national health and safety performance standar...